- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07942246
Healing and Improving Postnatal Nights Through Sleep (HIPNoS) (HIPNoS)
Healing and Improving Postnatal Nights Through Sleep (HIPNoS): A Randomized Controlled Trial Evaluating Perinatal Understanding of Mindful Awareness for Sleep (PUMAS) in Postpartum Women With Insomnia and Depression.
Insomnia and depression are highly prevalent during postpartum, but effective treatment options are severely limited. Perinatal Understanding of Mindful Awareness (PUMAS) combines behavioral sleep strategies and mindfulness-based exercises to improve sleep and mood during pregnancy. Indeed, PUMAS has been shown to effectively treatment comorbid insomnia and depression in pregnancy in controlled and uncontrolled trials. The present randomized controlled trial (RCT) will evaluate the effectiveness of PUMAS in a sample of postpartum women with comorbid insomnia and depression who will be randomized to to telemedicine PUMAS or online sleep hygiene education (SHE; enhanced usual care). Patients will be treated for six weeks followed by assessment after treatment then follow-up assessment 3-months later. The investigators hypothesize that PUMAS patients, relative to SHE patients, will report superior acute treatment effects on insomnia and depression as well as more durable effects at 3-month follow-up.
A tanulmány áttekintése
Állapot
Körülmények
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Heba Research Operations Manager
- Telefonszám: (248) 344-7363
- E-mail: hafaneh1@HFHS.ORG
Tanulmányi helyek
-
-
Michigan
-
Novi, Michigan, Egyesült Államok, 48377
- Henry Ford Medical Center - Columbus
-
Kapcsolatba lépni:
- Heba Research Operations Manager
- Telefonszám: (248) 344-7363
- E-mail: hafaneh1@HFHS.ORG
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the trial
- Participant must be able to engage in treatment (e.g., has internet access to attend telemedicine appointments or access online sleep hygiene materials).
- Aged 18 years or above.
- Postpartum 4-12 months at time of screening.
- Meets diagnostic criteria for DSM-5 insomnia disorder, acute (symptoms lasting ≥1 month).
- Clinically severe insomnia symptom severity (Insomnia Severity Index score ≥11).
- Clinically significant depression symptoms (Edinburg Postnatal Depression Scale score ≥10).
Exclusion Criteria:
- Sleep complaints primarily due to infant sleep problems as ascertained via clinical interview and/or describing the infant's sleep as a 'moderate' or 'serious' problem on the Brief Infant Sleep Questionnaire on the screening survey.
- Suicidal intent per the Columbus Suicide Severity Rating Scale (Suicidal ideation WITHOUT intent is NOT exclusionary).
- Current engagement in psychotherapy for insomnia disorder (current use of sleep aids [prescription, over-the-counter, or dietary supplements] is NOT exclusionary).
- Night or rotating shift work.
- Unreliable internet access that prevents a patient from being to engage with treatment and/or assessments.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Kettős
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)
Participants assigned to receive the PUMAS intervention. |
A six-week psychotherapy protocol combining behavioral sleep strategies with mindfulness exercises with all components tailored to peripartum. PUMAS was initially developed for pregnancy and has been shown to be safe and effective for alleviating insomnia, depression, and cognitive arousal during pregnancy. Early evidence from real-world clinic data has shown that postpartum women with insomnia show the same treatment benefits as prenatal patients, thereby offering early support for effectiveness in pregnancy. PUMAS will be delivered via telemedicine video with a therapist. |
|
Egyéb: Sleep hygiene education (SHE)
Participants assigned to receive six weeks of educational materials as an enhanced usual-care control. |
Sleep hygiene education (SHE) on maternal sleep and infant sleep. A six-week psychoeducation that will be delivered via six weekly information sheets that will be delivered via email to patients. Perinatal patients report that SHE is the most recommended non-pharmacological treatment suggested for their insomnia. In the real world, SHE is typically delivered in a one-shot information sheet (e.g., after visit summary). However, to match for contact frequency, SHE information will be delivered to patients weekly across six weeks, which also allows for providing greater information on maternal and infant sleep, thereby representing enhanced usual care practice. Although SHE practices improve sleep quality, SHE is not considered an effective standalone treatment for insomnia, therefore making SHE an interventional control comparator. |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Insomnia Severity Index (ISI)
Időkeret: The investigators will examine change in ISI from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
The Insomnia Severity Index is a commonly used self-report measure of insomnia symptoms that has been validated in peripartum. ISI scores range from 0 to 28 with higher scores indicating greater insomnia severity. |
The investigators will examine change in ISI from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Edinburgh Postnatal Depression Scale (EPDS)
Időkeret: The investigators will examine change in EPDS from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
The Edinburgh Postnatal Depression Scale (EDPS) is the most widely use depression measure in pregnancy and postpartum. EPDS scores range from 0 to 30 with higher scores indicating greater depression severity. |
The investigators will examine change in EPDS from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
|
Pre-Sleep Arousal Scale's cognitive factor (PSASC)
Időkeret: The investigators will examine change in PSASC from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
The Pre-Sleep Arousal Scale's Cognitive factor (PSASC) is a self-report measure of nocturnal cognitive arousal that has been validated in peripartum. PSASC scores range 8 to 40 with higher scores indicating greater nocturnal cognitive arousal. |
The investigators will examine change in PSASC from Pretreatment Baseline to Posttreatment (8 weeks after baseline), and at follow-up (4.5 months after baseline).
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Kutatásvezető: David A. Kalmbach, PhD, Henry Ford Health
Publikációk és hasznos linkek
Általános kiadványok
- Kalmbach DA, Cheng P, Roth T, Swanson LM, Cuamatzi-Castelan A, Roth A, Drake CL. Examining Patient Feedback and the Role of Cognitive Arousal in Treatment Non-response to Digital Cognitive-behavioral Therapy for Insomnia during Pregnancy. Behav Sleep Med. 2022 Mar-Apr;20(2):143-163. doi: 10.1080/15402002.2021.1895793. Epub 2021 Mar 15.
- Swanson LM, Flynn H, Adams-Mundy JD, Armitage R, Arnedt JT. An open pilot of cognitive-behavioral therapy for insomnia in women with postpartum depression. Behav Sleep Med. 2013;11(4):297-307. doi: 10.1080/15402002.2012.683902. Epub 2012 Dec 6.
- Kalmbach DA, Cheng P, Drake CL. A pathogenic cycle between insomnia and cognitive arousal fuels perinatal depression: exploring the roles of nocturnal cognitive arousal and perinatal-focused rumination. Sleep. 2021 Jun 11;44(6):zsab028. doi: 10.1093/sleep/zsab028.
- Kalmbach DA, Cheng P, Ong JC, Ciesla JA, Kingsberg SA, Sangha R, Swanson LM, O'Brien LM, Roth T, Drake CL. Depression and suicidal ideation in pregnancy: exploring relationships with insomnia, short sleep, and nocturnal rumination. Sleep Med. 2020 Jan;65:62-73. doi: 10.1016/j.sleep.2019.07.010. Epub 2019 Jul 22.
- Kalmbach DA, Cheng P, Sangha R, O'Brien LM, Swanson LM, Palagini L, Bazan LF, Roth T, Drake CL. Insomnia, Short Sleep, And Snoring In Mid-To-Late Pregnancy: Disparities Related To Poverty, Race, And Obesity. Nat Sci Sleep. 2019 Nov 4;11:301-315. doi: 10.2147/NSS.S226291. eCollection 2019.
- Kalmbach DA, Ong JC, Cheng P, Reffi AN, Swanson LM, Hirata M, Seymour GM, Castelan-Cuamatzi AS, Jennings MB, Pitts DS, Roth A, Roth T, Drake CL. A randomized controlled trial of telemedicine CBTI and PUMAS for prenatal insomnia: Reducing nocturnal cognitive arousal is a treatment mechanism for alleviating insomnia and depression during pregnancy. Sleep Med. 2025 Sep;133:106570. doi: 10.1016/j.sleep.2025.106570. Epub 2025 May 12.
- Kalmbach DA, Cheng P, Reffi AN, Ong JC, Swanson LM, Fresco DM, Walch O, Seymour GM, Fellman-Couture C, Bayoneto AD, Roth T, Drake CL. Perinatal Understanding of Mindful Awareness for Sleep (PUMAS): A single-arm proof-of-concept clinical trial of a mindfulness-based intervention for DSM-5 insomnia disorder during pregnancy. Sleep Med. 2023 Aug;108:79-89. doi: 10.1016/j.sleep.2023.05.026. Epub 2023 Jun 10.
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 19940
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .